Editorial {#S1}
=========

A recent study by Dr. Maria Antonietta De Luca demonstrated intravenous (IV) self-administration responding (nose-poking) for the synthetic cannabinoid JWH-018 \[1-pentyl-3-(1-naphthoyl)indole\] ([Figure 1](#F1){ref-type="fig"}) in an experimentally naïve, adult rat species \[[@R1]\]. This finding is unexpected since the phytocannabinoid (−)-trans-Δ9-tetrahydrocannabinol (Δ9-THC, [Figure 1](#F1){ref-type="fig"}), a primary psychoactive constituent in marijuana, has been reported to not maintain IV self-administration responding above vehicle levels in rats \[[@R2],[@R3]\] and rhesus monkeys \[[@R4]-[@R6]\]. IV self-administration of synthetic cannabinoids is not unprecedented since several synthetic cannabinoids have been found to maintain IV self-administration responding in experimentally naïve rats \[[@R1],[@R7]-[@R10]\], and mice \[[@R11]-[@R14]\]. However, the finding by Dr. De Luca is important because JWH-018 has been frequently found in K2/Spice preparations \[[@R15]-[@R17]\] and there continues to be an increase in the abuse and non-medical use of various synthetic cannabinoids worldwide \[[@R15]-[@R17]\]. Further, the use of marijuana has been recently legalized in two states of the U.S.

The finding by Dr. De Luca is unexpected since response-dependent changes in visual stimuli were not presented at the time when the compound was self-injected. Self-administration of synthetic cannabinoids in most studies has been demonstrated in the presence of response-dependent changes in visual stimuli \[[@R3],[@R7]-[@R9],[@R11],[@R12],[@R14]\]. The Dr. De Luca\'s finding is important because the dopamine D2-like agonist, quinpirole, was not self-administered above vehicle levels in experimentally naïve rats even when a response-dependent injection-paired visual stimulus was presented \[[@R18],[@R19]\]. Further, (-)-nicotine was not self-administered above vehicle levels in experimentally naïve rats in the absence of an injection-paired visual stimulus \[[@R20]\]. In addition, the rate of acquisition of self-administration reported by Dr. De Luca is also unexpected: 100% of fourteen rats assessed \[[@R1]\]. To put this in context, maximal self-administration acquisition rates of the synthetic cannabinoid WIN 55,212-2 using drug naïve, adult rats were reported to be 85.7 % (12 out of 14) at 0.0125 mg/kg/injection \[[@R7]\] or 60.0% (3 out of 5) at 0.01 mg/kg/injection \[[@R3]\]. Finally, the finding by Dr. De Luca stands in marked contrast to the reinforcing effects of Δ9-THC. Despite the demonstrated effectiveness of Δ9-THC as a positive reinforcer in experimentally naïve squirrel monkeys \[[@R21]\], Δ9-THC has been reported to fail to maintain IV self-administration responding above vehicle levels in rats \[[@R2],[@R3]\] and rhesus monkeys \[[@R4]-[@R6]\]. Thus, it appears that JWH-018 is a more effective positive reinforcer in rats than Δ9-THC.

As mentioned above, the abuse of synthetic cannabinoids is increasing \[[@R15],[@R16]\]. Despite the low effectiveness of the phytocannabinoid Δ9-THC as a positive reinforcer in a rat species \[[@R2],[@R3]\], Dr. De Luca found a relatively high capacity of the synthetic cannabinoid JWH-018 to induce self-administration responding above vehicle levels in experimentally naïve rats \[[@R1]\]. Unexpectedly, Dr. De Luca also demonstrated self-administration of the endocannabinoid 2-arachidonoylglycerol in experimentally naïve rats \[[@R22]\]. These findings suggest that rats will be a useful model for the further assessment of the abuse potential of various synthetic cannabinoids.
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